Second, by curating recent phase I–III and real-world data we reveal a clear trend towards neoadjuvant and adjuvant ICI use; we therefore champion peri-operative immunotherapy as a high-yield setting for upcoming studies, particularly in patients with intermediate-risk genetic signatures.
← all excerpts
Next-generation immunotherapies for head and neck squamous cell carcinoma: targeting novel immune checkpoints.
2
—
—
The sentences
The incorporation of polyclonal antibodies and combination chemotherapy strategies is also deemed highly significant.